Plant Lectin and Selenium Composition for Mucosal Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cancer patients undergoing or having undergone oncological radiation or chemotherapy experience a range of symptoms including mucosal tissue damage, nausea, vomiting, diarrhea, fatigue, weakness, skin irritation, and joint discomfort, which are not effectively alleviated by conventional treatments, and these treatments often have significant side effects.
Innovation Solution
A composition comprising at least one plant lectin, one proteolytic enzyme, and one selenium compound, administered orally, in specific daily doses, to provide mucosal protection and alleviate a spectrum of symptoms, including mucosal tissue regeneration and symptom relief.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for mucosal tissue damage and symptom relief in cancer patients, then treatment protocols are established, but side effects are significant and symptom relief is insufficient
Solution Approach 1:
The patent combines multiple active ingredients (proteolytic enzymes, plant lectins, selenium compounds, and other supportive substances) into a single composite preparation called Equizym. This merging of different therapeutic agents with complementary mechanisms of action allows for synergistic effects that provide comprehensive symptom relief while reducing individual drug dosages and their associated side effects.
Solution Approach 2:
The invention uses a composite formulation containing proteolytic enzymes (bromelain, papain, trypsin, chymotrypsin), plant lectins (from Viscum album, Ginkgo biloba, and other sources), selenium compounds, and other beneficial substances. This composite material approach enables multiple therapeutic functions in one preparation, addressing various symptoms simultaneously while improving tolerability.
2Reliability
If chemotherapy and radiation therapy doses are increased to improve cancer treatment effectiveness, then tumor control improves, but mucosal tissue damage and symptom severity increase
Solution Approach 1:
The patent applies Equizym preparation before, during, and after chemotherapy and radiation therapy to protect mucosal tissues from damage. The proteolytic enzymes reduce inflammation and edema, plant lectins support immune function and cell regulation, and selenium compounds provide antioxidant protection. This beforehand cushioning approach allows patients to receive full therapeutic doses of cancer treatment while minimizing mucosal side effects.
Solution Approach 2:
The composite preparation acts as an intermediary protective agent between the cancer treatment and the patient's healthy tissues. It mediates the harmful effects of chemotherapy and radiation on mucosal membranes while allowing the therapeutic effects on tumors to proceed unabated, thereby decoupling treatment effectiveness from side effect severity.
3Ease of operation
If single-ingredient preparations are used for symptom management, then treatment simplicity is maintained, but comprehensive symptom relief is insufficient
Solution Approach 1:
The patent merges multiple therapeutic agents with different mechanisms of action into a single ready-to-administer preparation. This includes proteolytic enzymes for anti-inflammatory effects, plant lectins for immunomodulation, selenium for antioxidant protection, and other supportive substances. Patients receive comprehensive symptom relief through one simple daily dose rather than multiple separate medications.
Solution Approach 2:
The Equizym preparation is designed with multi-functionality to address various symptoms simultaneously: it reduces inflammation, supports immune function, protects mucosal tissues, alleviates digestive symptoms, and improves overall well-being. This universal preparation replaces multiple single-function medications while maintaining ease of administration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of plant lectins, proteolytic enzymes, and selenium significantly improves mucosal protection and relieves various symptoms in cancer patients, enhancing the tolerability of chemotherapy and radiation therapy, reducing side effects, and improving overall quality of life.
Implementation Method 1
proteolytic enzymes
Implementation Method 2
selenium compound
Data Source
Figure 1
Figure 2
AI summary
Use of a composition comprising at least one plant lectin, proteolytic enzyme and a selenium compound to produce a drug or dietary supplement, preferably for the balanced diet, and for simultaneous reduction of a spectrum of symptoms comprising nausea, vomiting/diarrhea, dry mucous membranes, joint pain, fatigue/weakness and skin irritation, in individuals who have undergone/undergoing radiotherapy and/or chemotherapy, is claimed. ACTIVITY : Anabolic; Antiemetic; Antidiarrheic; Analgesic; CNS-Gen.; Muscular-Gen. MECHANISM OF ACTION : None given.